EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France

BACKGROUND EQOFIX is a medicoeconomic study that analyzed the health‐related quality of life (HRQoL) and costs of care of the moderate and severe forms of hemophilia B, treated on demand or by prophylaxis with either plasma‐derived Factor IX (pdFIX) or recombinant FIX (rFIX). STUDY DESIGN AND METHOD...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Transfusion Ročník 55; číslo 7; s. 1787 - 1797
Hlavní autori:	Polack, Benoît, Calvez, Thierry, Chambost, Hervé, Rothschild, Chantal, Goudemand, Jenny, Claeyssens, Ségolène, Borel-Derlon, Annie, Bardoulat, Isabelle, Maurel, Frédérique, Woronoff-Lemsi, Marie-Christine
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Blackwell Publishing Ltd 01.07.2015 Wiley Wiley Subscription Services, Inc
Predmet:	[INFO.INFO-BT]Computer Science [cs]/Biotechnology Adolescent Adult Child Cohort Studies Costs Costs and Cost Analysis Economics and Finance Factor IX Factor IX - administration & dosage Factor IX - economics Female France Hematology Hemophilia Hemophilia B Hemophilia B - drug therapy Hemophilia B - economics Hemorrhage Hemorrhage - economics Hemorrhage - prevention & control Human health and pathology Humanities and Social Sciences Humans Life Sciences Male Middle Aged Quality of Life Santé publique et épidémiologie France
ISSN:	0041-1132, 1537-2995, 1537-2995
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	BACKGROUND EQOFIX is a medicoeconomic study that analyzed the health‐related quality of life (HRQoL) and costs of care of the moderate and severe forms of hemophilia B, treated on demand or by prophylaxis with either plasma‐derived Factor IX (pdFIX) or recombinant FIX (rFIX). STUDY DESIGN AND METHODS The primary objectives were evaluations of the impact of hemophilia B on HRQoL and of the costs associated with its management. The secondary objectives were evaluations of the clinical efficacy and costs of care of pdFIX and rFIX. In this observational study we included and followed for 1 year severe and moderate hemophilia B patients without inhibitor. HRQoL was evaluated through generic and disease‐specific questionnaires. Information on the health resources consumed was collected every 3 months. RESULTS The EQOFIX cohort was composed of 155 patients, including 51 children and 104 adults, with 114 having severe disease and 41 having moderate disease. The regimens were prophylactic for 61 and on demand for 94. Altogether, 78 were treated with rFIX and 77 with pdFIX. There was no difference in the QoL between the pdFIX and rFIX treatments. The extra cost of prophylaxis was €22,605 per bleeding event prevented. The consumption of FIX was 1.4‐fold higher for the patients treated with rFIX than for the patients treated with pdFIX. CONCLUSION Our findings in a cohort composed of 25% of the French population of moderate and severe hemophilia B patients show, with similar clinical and HRQoL results, that treatment with rFIX is more expensive than treatment with pdFIX.
Bibliografia:	Supported by Laboratoire Français du Fractionnement et des Biotechnologies (LFB). The funding source had no role in the study design; in the collection, analysis or interpretation of the data; in the writing of the report; or in the decision to submit this paper istex:411FD320F14D6E026D99CAF3B7A21DDA4BB14E75 ark:/67375/WNG-HR44KJ8J-4 ArticleID:TRF13016 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23
ISSN:	0041-1132 1537-2995 1537-2995
DOI:	10.1111/trf.13016